
Inhibrx Biosciences Investor Relations Material
Latest events

Q2 2025
12 Aug, 2025

Q4 2024
16 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Inhibrx Biosciences Inc
Access all reports
Inhibrx Biosciences Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutic candidates. The company's work is centered on leveraging its proprietary protein engineering platforms to design and develop therapies aimed at treating serious and life-threatening conditions. Inhibrx's pipeline includes multiple candidates that target various pathways involved in cancer and other critical diseases, with several programs in clinical trials. Inhibrx Biosciences is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
INBX
Country
🇺🇸 United States